Abstract
Background: We conducted a translational study on enrolled patients in a phase I/II trial of anti PD-L1 durvalumab (Du) combined with cetuximab (Ctx) and radiotherapy (RT) in locally advanced squamous cell carcinoma of the head and neck (DUCRO trial, NCT03051906). The aim was to evaluate the immunological profile and to investigate the dynamics of cytokine production in peripheral blood mononuclear cells (PBMCs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
